Home Alzheimer’s Disease Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates

Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates

The open-label treatment cycle (cycle 2) of the pivotal phase III FLASH (Fluorescent Light Activated Synthetic Hypericin) study found that continued treatment with SGX301 (synthetic hypericin) twice weekly for 12 weeks increased the positive response rate to 40% (P < 0.0001 compared to placebo and P < 0.0001 compared to 6-weeks treatment), according to Soligenix, the agent’s developer. 

SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma (CTCL). These highly statistically significant results confirm the benefit of continued treatment with SGX301 in patients with CTCL.

“As anticipated, the data continues to become more compelling with extended SGX301 treatment,” lead investigator Ellen Kim, MD, director of the Dermatology Clinic at the Perelman Center for Advanced Medicine. “This treatment response is comparable to other, less safe,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Recent Comments